A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Flutafuranol F 18 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics; Registrational
- Sponsors Navidea Biopharmaceuticals
- 25 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 25 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 24 Jul 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.